Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
To confirm that concomitant administration of aminoglutethimide (AG) reduces plasma levels of medroxyprogesterone acetate (MPA), MPA levels were assayed in six patients with advanced breast cancer receiving the two agents. Patients had disease resistant to AG and were studied during conversion to therapy with MPA. Hydrocortisone was discontinued at the commencement of study and MPA introduced and given at a constant dose of 800 mg daily while AG was reduced in dose from 250 mg b.d. to 125 mg b.d. and then discontinued. MPA levels were measured after two weeks at each dose of AG and after two weeks on MPA alone. Mean MPA levels showed a progressive and significant (P less than 0.01) rise as the AG dose was reduced--180 ng ml-1, 250 ng ml-1 and 740 ng ml-1 respectively. MPA levels were always in excess of the accepted therapeutic level of 100 ng ml-1 and plasma cortisol levels fell in parallel with the rise in MPA levels.
Halpenny
O
O
Department of Clinical Haematology/Oncology, St. James's Hospital, Dublin, Ireland.
Bye
A
A
Cranny
A
A
Feely
J
J
Daly
P A
PA
D000328:Adult; D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D015996:Survival Rate
D000970:Antineoplastic Agents; D000616:Aminoglutethimide; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D006854:Hydrocortisone